RCT | Discontinuation vs. continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis.

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials – The Lancet Respiratory Medicine (free registration required)

Commentary on Twitter

NEW Article—Discontinuing daily hypertonic saline or dornase alfa in #CFTR modulator-treated individuals with #cysticfibrosis: the SIMPLIFY study

From Nicole Mayer-Hamblett & colleagues https://t.co/LwVctcOlTq#NACFC2022 @CF_Foundation pic.twitter.com/OnDe8rUoPx

— The Lancet Respiratory Medicine (@LancetRespirMed) November 4, 2022